Calcitriol

Intervention Vitamin D Approved 1978

2 papers3 findings

PubChem 5280453 ChEBI 17823 MeSH D002117

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
89 trials, 33 with no results posted

Funder: National Natural Science Foundation of China

Animals1

Outcomes

CDKN1B

downin mouse cells1

1 study

Calcitriol decreases CDKN1B in mouse cells.
Cellsbone marrow mesenchymal stem cells
Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation
European journal of endocrinology3 Aug 2026

Trials

Approved

FDA Rocaltrol
17 Aug 1978
FDA Calcijex
25 Sep 1986Discontinued
FDA Rocaltrol
20 Nov 1998Bone Diseases, Metabolic, Hyperparathyroidism, Secondary, Hypocalcemia, Hypoparathyroidism, chronic renal failure
FDA Vectical
23 Jan 2009Plaque Psoriasis

Repurposing

Osteoporosis
Phase 4Status unknown2 trials
Kidney disease
Phase 3Results posted1 trial
Pneumonia
Phase 4Results posted1 trial
Vitamin D deficiency
Phase 4Recruiting5 trials
Adenoma
Phase 3Terminated1 trial
Neoplasm
Phase 4Results posted1 trial

40 of 44

Infertility
Phase 4Completed2 trials
Autoimmune disease
Phase 4Status unknown1 trial
Vascular calcification
Phase 4Status unknown3 trials
Proteinuria
Phase 4Completed4 trials
Diabetic nephropathy
Phase 4Status unknown3 trials
Renal insufficiency
Phase 4Terminated2 trials
Glomerulonephritis
Phase 4Completed2 trials
Friedreich ataxia
Phase 4Completed1 trial
Tuberous sclerosis
Phase 3Completed1 trial
Obesity
Phase 2Results posted1 trial
Bone fracture
Phase 2Results posted1 trial
Acute kidney injury
Phase 2Results posted1 trial
COVID-19
Phase 2Completed1 trial
Type 1 diabetes
Phase 2Completed1 trial
Sepsis
Phase 2Results posted1 trial
Systemic lupus erythematosus
Phase 2Status unknown1 trial
Myelodysplastic syndrome
Phase 2Completed2 trials
Psoriasis
Phase 2Results posted4 trials
Critical illness
Phase 2Results posted1 trial
Leukemia
Phase 2Results posted1 trial
Septic shock
Phase 2Results posted1 trial
Cholangiocarcinoma
Phase 2Status unknown1 trial
Lupus nephritis
Phase 2Status unknown1 trial
Male infertility
Phase 2Results posted1 trial
Non small cell lung carcinoma
Phase 2Status unknown3 trials
Pancreatic neoplasms
Phase 2Completed1 trial
Precancerous condition
Phase 2Terminated1 trial
Hypertension
Early phase 1Terminated1 trial
Postmenopausal osteoporosis
Early phase 1Status unknown1 trial
Anemia
Early phase 1Completed1 trial
Melanoma
Phase 1/2Results posted1 trial
Alopecia
Phase 1Results posted1 trial
Glioblastoma
Phase 1Completed1 trial
Bone disease
Early phase 1Results posted1 trial

In trials

Chronic renal insufficiency
Phase 4Results posted9 trials
Chronic kidney failure
Phase 4Results posted7 trials
Chronic Kidney Disease-Mineral and Bone Disorder
Phase 4Status unknown4 trials
Familial Hypophosphatemic Rickets
Phase 4Status unknown2 trials
Cholestasis
Phase 4Recruiting1 trial
Hypercalcemia
Phase 4Terminated1 trial

All 17

Prostatic Neoplasms
Phase 3Terminated14 trials
Hyperparathyroidism
Phase 3Results posted2 trials
Rare Diseases
Phase 3Completed2 trials
Osteopetrosis
Phase 3Completed1 trial
Breast neoplasm
Phase 2Results posted2 trials
Castration-resistant prostate cancer
Phase 2Terminated1 trial
Precursor cell lymphoblastic leukemia lymphoma
Phase 2Results posted1 trial
Lung Neoplasms
Phase 1/2Completed2 trials
Protocol specific unspecified adult solid tumor
Phase 1Completed3 trials
Attention Deficit Disorder with Hyperactivity
Phase 1Results posted2 trials
Craniopharyngioma
Phase 1Completed1 trial

Stopped

NCT00664430TerminatedSecondary hyperparathyroidism
Low enrollment rate
NCT01725113TerminatedSecondary hyperparathyroidism
Nationwide shortage of study meds in 2013 loss of funding \& competing studies
NCT00623974TerminatedHypocalcemia
Terminated due to slow accrual.
NCT00273338TerminatedProstatic Neoplasms
DSMB
NCT00486512TerminatedAdenoma
The overall program was terminated
NCT03261336TerminatedCastration-resistant prostate cancer
can not meet enrollment

All 9

NCT00118066TerminatedPrecancerous condition
Slow accruaL, lack of scientific progress
NCT04386811TerminatedAttention Deficit Disorder with Hyperactivity
Following Yale University resuming in-person research activities, the investigators no longer had dedicated funding for the study and were unable to secure additional funding to meet the research goals.
NCT00585442TerminatedHypertension
Lack of quality data